The Ohio State University Comprehensive Cancer Center (OSUCCC –James) places the highest priority on ensuring the safety of patients participating in clinical trials. Every therapeutic interventional trial conducted at the OSUCCC –James must include a plan for safety and data monitoring.
The data and safety monitoring plan will involve the continuous evaluation of safety, data quality and data timeliness. Investigators will conduct continuous review of data and patient safety at their regular disease group meetings (at least monthly) and the discussion will be documented in the minutes.
The principal investigator (PI) of the trial will review toxicities and responses of the trial where applicable at these disease group meetings and determine if the risk/benefit ratio of the trial changes. Frequency and severity of adverse events will be reviewed by the PI and compared to what is known about the agent/device from other sources; including published literature, scientific meetings and discussions with the sponsors, to determine if the trial should be terminated before completion.
Serious adverse events and responses will also be reviewed by the OSUCCC –James Data and Safety Monitoring Committee (DSMC). The PI will also submit a progress report (biannually for Phase II and quarterly for Phase I) that will be reviewed by the committee per the DSMC plan. All reportable serious adverse events will also be reported to the Institutional Review Board (IRB) of record as per the policies of the IRB.
To download a PDF of Data Safety Monitoring Plan, click here